Aurinia Pharmaceuticals Inc
12.22-0.41 (-3.25%)
Oct 29, 4:00:01 PM EDT · NasdaqGM · AUPH · USD
Key Stats
Market Cap
1.61BP/E (TTM)
28.42Basic EPS (TTM)
0.43Dividend Yield
0%Recent Filings
8-K
Aurinia boosts revenue, repurchases
Aurinia Pharmaceuticals reported Q2 2025 revenue of $70.0 million, up 22% year-over-year, driven by $66.6 million in LUPKYNIS net product sales amid new ACR guidelines boosting first-line use. The company swung to net income of $21.5 million from a slim $0.7 million profit last year, while boosting its share repurchase plan by $150 million after buying back $90.8 million in shares. Cash stood at $315.1 million. Aurinia raised 2025 revenue guidance to $260-270 million. Strong sales fuel returns to shareholders.
10-Q
Q2 FY2025 results
Aurinia Pharmaceuticals posted solid Q2 FY2025 results, with total revenue climbing 22% year-over-year to $70.0 million on $66.6 million in net product sales, up 21% from stronger LUPKYNIS uptake in lupus nephritis markets. Gross margin expanded to 90% from 84%, while operating income swung to $20.1 million from a $1.5 million loss, fueled by 42% lower SG&A after 2024 restructurings that trimmed headcount. Diluted EPS hit $0.16 on 137.5 million shares, consistent with net income of $21.5 million. Cash from operations reached $45.5 million year-to-date, offset by $90.8 million in share repurchases; liquidity stood at $315.1 million, with $75.4 million in Monoplant finance lease debt through 2030. Patent challenges from generic filers loom as a key risk.
8-K
Positive Phase 1 for AUR200
Aurinia Pharmaceuticals announced positive Phase 1 results for aritinercept (AUR200), a dual BAFF/APRIL inhibitor, on June 30, 2025. Single doses up to 300 mg were well tolerated, with no serious adverse events, and drove robust immunoglobulin reductions—up to 48% in IgA, 55% in IgM, and 20% in IgG by Day 28—supporting once-monthly dosing. The company plans clinical studies in at least two autoimmune diseases in the second half of 2025. Yet development risks loom large.
8-K
Aurinia approves equity plan
Aurinia Pharmaceuticals shareholders approved an amended and restated Equity Incentive Plan at the May 15, 2025 annual meeting, reserving 20,836,773 common shares for employee incentives while enforcing a one-year minimum vesting. The board elected six directors, including Kevin Tang and Peter Greenleaf, and ratified PricewaterhouseCoopers as auditors. Bylaws now let shareholders set director numbers. This bolsters talent retention amid biotech volatility.
8-K
Aurinia Q1 revenue jumps 24%
Aurinia Pharmaceuticals reported Q1 2025 revenue of $62.5 million, up 24% from $50.3 million last year, driven by $60.0 million in LUPKYNIS net product sales that surged 25%. The company swung to a $23.3 million net income from a prior $10.7 million loss, while repurchasing 5.8 million shares for $47.4 million; cash stood at $312.9 million. It reiterated 2025 guidance of $250-$260 million total revenue. Strong sales reflect guideline updates favoring early LUPKYNIS use, yet restructuring costs linger.
IPO
Employees
Sector
Industry
AEON
AEON Biopharma, Inc.
0.88-0.05
ALMS
Alumis Inc.
4.71-0.10
AURA
Aura Biosciences, Inc.
6.14-0.23
AURX
Nuo Therapeutics, Inc.
2.29+0.00
BMRN
BioMarin Pharmaceutical Inc.
51.86-1.63
LBRX
LB Pharmaceuticals Inc
15.65-0.92
LGND
Ligand Pharmaceuticals Incorpor
184.52-4.35
NKTR
Nektar Therapeutics
59.63-1.29
ORKA
Oruka Therapeutics, Inc.
27.61+0.17
TBPH
Theravance Biopharma, Inc.
14.17+0.07